drugset
drugset / Trial / NCT01172873

D-Cycloserine Augmentation to CBT With Exposure and Response Prevention in Adults and Adolescents With OCD

NCT01172873 ↗

Completed 16 enrolled New York State Psychiatric Institute Emory University · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a single site, open-label, feasibility study of cognitive behavioral therapy with exposure and response prevention (CBT/ERP) adding the augmentation of D-cycloserine (DCS) for adolescents ages 12-17 with Obsessive Compulsive Disorder (OCD) who are partial or non-responders to first line treatments of CBT or pharmacotherapy.

Timeline

Start
2008-09
Primary completion
2010-09
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cycloserine Small molecule 50 mg —

Indications

obsessive-compulsive disorder